Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 studyKrzysztof Selmaj, Erik Wallström, David K.B. Li et al.|The Lancet Neurology|2013Cited by 233
Loss of nocturnal blood pressure fall in various extrapyramidal syndromesClaudia Schmidt, Tjalf Ziemssen, Silke Prieur et al.|Movement Disorders|2009Cited by 113
Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple SclerosisLudwig Kappos, Krzysztof Selmaj, David K.B. Li et al.|JAMA Neurology|2016Cited by 103
Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)Ellen M. Mowry, Richard A. Rudick, Robert Bermel et al.|Frontiers in Neurology|2020Cited by 91
Multiple sclerosis registries in Europe – An updated mapping surveyAnna Glaser, Christoph Thalheim, Alexander Stahmann et al.|Multiple Sclerosis and Related Disorders|2018Cited by 67